FDA grants CRL for Bristol-Myers, AstraZeneca diabetes drug NDA
Dapagliflozin, an inhibitor of SGLT2, is being investigated to assess the safety and efficacy in improving glycemic control in adults with type 2 diabetes, for use as a
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.